Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNX-5422 and Ibrutinib in CLL with BTK Mutation
NCT02914327Phase 1Withdrawn
- Sponsor
- Esanex, Inc.
- Start
- Feb 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of snx-5422 in chronic lymphocytic leukemia (CLL), sponsored by Esanex, Inc. Primary endpoint: Efficacy of the combination of SNX-5422 and ibrutinib at 52 weeks. Planned start Feb 2017; status: withdrawn.
02
Drugs
snx-5422
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02914327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914327.